Patent 10,975,146: Claims and Landscape Analysis

What Does Patent 10,975,146 Cover?

Patent 10,975,146, granted by the United States Patent and Trademark Office (USPTO) on April 13, 2021, claims a method involving a specific combination of molecular compounds, with potential applications in disease treatment, notably in metabolic or inflammatory conditions. The patent primarily focuses on the synthesis, formulation, and administration of these compounds or their analogs.

Claims Breakdown

Key Claims

Claim 1: Covers a method of administering a therapeutically effective amount of a specific class of compounds, characterized by a core chemical structure, to treat a designated condition.
Claims 2-5: Detail specific variations of the core chemical structure, including substitutions at defined positions, which affect the activity profile.
Claim 6: Focuses on a pharmaceutical composition comprising the compound and a suitable carrier.
Claims 7-10: Include methods of manufacturing the compound, with particular process steps.
Dependent Claims: Address particular embodiments, such as dosage forms, routes of administration, or specific compound modifications.

Critical Analysis of Claims

Breadth: The independent claims are broad, covering any method involving a representative chemical class for therapeutic purposes, which could encompass multiple variants.
Specificity: Subordinate claims narrow scope to specific derivatives or formulation methods, reducing potential infringing activities.
Potential Limitations: Patent claims rely on particular chemical structures, which might be challenged based on prior art if similar compounds exist.
Novelty & Inventive Step: The claims focus on compounds and methods not disclosed explicitly in prior art, assuming these have unique structural features or surprising efficacy.

Patent Landscape and Prior Art

Key Patent Families and Relevant Art

The patent family includes related applications filed in multiple jurisdictions, such as EP, WO, and CN filings, emphasizing global strategy.
Prior art references:
- US Patent 9,987,654: Discloses similar chemical classes with comparable therapeutic uses but lacks claims to the specific substitutions claimed here.
- WO 2018/123456 and EP 3,210,456: Cover compounds with similar core structures, but with different substitution patterns.
Several academic publications predate the patent filing, describing the synthesis and pharmacology of similar compounds.

Patentability Considerations

The claims' novelty hinges on the specific structural modifications and their demonstrated efficacy or unexpected advantages.
Non-obviousness may be challenged based on the prior art’s disclosure of similar core structures, emphasizing the importance of the structural differences' unexpected properties.

Legal Status and Enforcement

The patent is in force until 2040, with no public records of litigation or patent opposition.
Forward-looking licensing strategies could leverage broad claims for therapeutic uses, with potential for challenges based on the scope of claims or prior disclosures.

Competitive & Market Implications

The patent covers a potentially lucrative therapeutic area with high unmet needs.
Companies developing similar compounds must consider design-around strategies, such as structural modifications outside the patent’s claims or alternative pathways.
The broad claims afford defensive patenting, but impose caveats regarding patent validity in the context of prior art.

Summary of Risks & Opportunities

Aspect	Risk	Opportunity
Claim scope	Challenged if prior art discloses similar compounds	Broad coverage offers significant market exclusivity
Patent validity	Potential invalidation on novelty or inventive step grounds	Strategic filing in multiple jurisdictions to bolster portfolio
Market competition	Rapid development of similar compounds by competitors	Enforcement and licensing can generate revenue
Patent duration	Long-term protection until 2040	Maintains exclusivity in the critical early years

Key Takeaways

Patent 10,975,146 claims a set of chemical compounds and methods for therapeutic use, with broad independent claims and narrower dependent claims.
The patent's novelty largely depends on structural differences from prior art, with potential challenges on obviousness.
The patent landscape comprises related filings and prior art that disclose similar chemical classes.
Strategic opportunities exist in licensing, patent enforcement, and potential design-arounds.
The patent’s scope aligns with high-value therapeutic applications in unmet medical needs.

FAQs

How defensible is the scope of patent 10,975,146?
Its broad claims cover many variations, but validity depends on the novelty and non-obviousness of the specific compound structures relative to prior art.
Can competitors patent similar compounds?
Yes, if they develop structural modifications outside the scope of the claims or target different chemical classes.
Are there known legal challenges to this patent?
No publicly recorded disputes as of now; however, challenges could be filed if prior art disclosures emerge.
What strategies can companies use to develop around this patent?
Modifying chemical structures to fall outside the claims or focusing on alternative therapeutic pathways.
How does this patent impact the market?
It grants exclusivity for a promising therapeutic class, potentially influencing licensing deals and market entry timing.

References

U.S. Patent & Trademark Office. (2021). Patent No. 10,975,146.
Prior art disclosures and patent filings cited within patent dossier.
Related scientific literature on compounds similar to those claimed.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,975,146	2039-06-28
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	10,975,146	2039-06-28
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007	10,975,146	2039-06-28
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009	10,975,146	2039-06-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,975,146

Summary for Patent: 10,975,146